Thermal laser arterial injury and prostacyclin administration in dogs: thrombotic and hyperplastic consequences.
Angioplasty is considered as an alternative to surgical reconstruction of arteriosclerotic vessels especially since lasers and atherectomy devices have become clinically available. However, the resulting arterial injury may lead to acute thrombotic occlusion and chronic restenosis because of hyperplastic vascular repair. The purpose of this experimental study was to evaluate the consequences of thermal laser arterial injury on platelet deposition and myointimal hyperplasia in dog femoral arteries. An intraarterial, short-term prostacyclin (PGI2) infusion was given to evaluate the antithrombotic and antiproliferative effects of this drug. Severe arterial necrosis, partly carbonized and vacuolized, extending to the adventitia was induced by a transluminal heated laser probe motion. The platelet deposition after one hour was 33.62 +/- 6.56 (x 10(6)/cm2.) (mean +/- SEM) without prostacyclin, after 40 ng/kg/min prostacyclin (PGI2) 24.70 +/- 5.45 and after 400 ng/kg/min 9.3 +/- 2.26 (p less than 0.005 no PGI2 vs 400 ng/kg/min PGI2). Myointimal hyperplasia was present eight weeks after thermal laser vascular injury independent of the initially administered prostacyclin. In conclusion, acutely thrombotic and chronically hyperplastic femoral arteries were found following transluminal thermal arterial injury in dogs. Prostacyclin administration could be clinically beneficial in reducing acute vascular thrombosis following thermal angioplasty. Short-term use of this substance, however, may not prevent a hyperplastic response to angioplasty.
Hehrlein
C
C
Lasers and Applied Technologies Laboratory, Heineman Medical Research Center, Charlotte, NC.
Svenson
R H
RH
McKusik
A P
AP
Chuang
C H
CH
Tuntelder
J R
JR
Tatsis
G P
GP
Littmann
L
L
Thompson
M
M
D016342:Angioplasty, Laser / Q000009:adverse effects* / Q000295:instrumentation; D000818:Animals; D004195:Disease Models, Animal; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D011464:Epoprostenol / Q000008:administration & dosage*; D005263:Femoral Artery / Q000293:injuries* / Q000473:pathology; D006965:Hyperplasia / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D007261:Infusions, Intra-Arterial; D009336:Necrosis; D010973:Platelet Adhesiveness / Q000187:drug effects / Q000528:radiation effects; D011183:Postoperative Complications / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control; D013927:Thrombosis / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control; D013997:Time Factors
D011464:Epoprostenol